Grundläggande statistik
| CIK | 1156295 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Seracare Life Sciences Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 1, 2012 |
15-12G 1 v31129115-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-34105 SERACARE LIFE SCIENCES, INC. (Exact nam |
|
| April 25, 2012 |
SeraCare Life Sciences Introduces New Executives Company Supports Growth of Precision Medicine For Immediate Release Company Contact: Marsha Ann Marsh Agency Contact: Chris Hoag SeraCare Life Sciences, Inc. |
|
| April 25, 2012 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commission |
|
| April 24, 2012 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SERACARE LIFE SCIENCES, INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SERACARE LIFE SCIENCES, INC. ARTICLE ONE The name of the corporation is SeraCare Life Sciences, Inc. (the "Corporation") ARTICLE TWO The address of the Corporation's registered office in the State of Delaware is 1209 Orange Street, City of Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address |
|
| April 24, 2012 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF SERACARE LIFE SCIENCES, INC. A Delaware corporation Effective as of April 20, 2012 ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be located at 160 Greentree Drive, Suite 101, in the City of Dover, County of Kent, 19904. The registered agent of the corporation for service of process |
|
| April 24, 2012 |
8-K 1 v3102568k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction |
|
| April 20, 2012 |
As filed with the Securities and Exchange Commission on April 20, 2012 Registration Statement No. |
|
| April 20, 2012 |
As filed with the Securities and Exchange Commission on April 20, 2012 Registration Statement No. |
|
| March 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 12, 2012 |
SRLS / Seracare Life Sciences Inc / Wellington Trust Co NA - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SeraCare Life Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 81747T104 (CUSIP Number) February 29, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SeraCare Life Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 81747T104 (CUSIP Number) February 29, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2012 |
EX-10.1 2 v304762ex10-1.htm Exhibit 10.1 EXPLANATORY NOTE TO THIS EXHIBIT The Company’s representations and warranties included in this First Amendment Agreement were made to each of the lenders hereunder. These representations and warranties were made as of specific dates, only for purposes of this First Amendment Agreement and for the benefit of the parties thereto. These representations and war |
|
| February 28, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2012 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, dated as of February 27, 2012 (this “Amendment”), is entered into by and among Project Plasma Holdings Corporation, a Delaware corporation (“Parent”), Project Plasma Merger Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and SeraCare Life Sciences, Inc., a Delaw |
|
| February 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2012 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, dated as of February 27, 2012 (this “Amendment”), is entered into by and among Project Plasma Holdings Corporation, a Delaware corporation (“Parent”), Project Plasma Merger Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and SeraCare Life Sciences, Inc., a Delaw |
|
| February 22, 2012 |
SRLS / Seracare Life Sciences Inc / Shkreli Martin Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) SeraCare Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81747T104 (CUSIP Number) Martin Shkreli MSMB Capital Management, LLC 330 Madison Ave., 6th floor New York, NY 10017 (646) 495 - 5073 (Name, Address |
|
| February 14, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* SeraCare Life Sciences, Inc. (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 81747T104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2012 |
Exhibit 2.1 Agreement And Plan Of Merger dated as of February 12, 2012 among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. TABLE OF CONTENTS Article 1 THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Effects of the Merger 2 Section 1.3. Closing 2 Section 1.4. Consummation of the Merger. 3 Section 1.5. Organizational Documents; Directors and Of |
|
| February 14, 2012 |
SERACARE LIFE SCIENCES, INC. INDEMNIFICATION AGREEMENT Exhibit 10.1 SERACARE LIFE SCIENCES, INC. INDEMNIFICATION AGREEMENT This Agreement is made as of February , 2012 by and between SeraCare Life Sciences, Inc., a Delaware corporation (the “Corporation”), and (the “Indemnitee”), a director or officer of the Corporation. WHEREAS, the stockholders of the Corporation have determined, by virtue of their adoption of Article VII of the Corporation’s Certif |
|
| February 14, 2012 |
SERACARE LIFE SCIENCES, INC. INDEMNIFICATION AGREEMENT Exhibit 10.1 SERACARE LIFE SCIENCES, INC. INDEMNIFICATION AGREEMENT This Agreement is made as of February , 2012 by and between SeraCare Life Sciences, Inc., a Delaware corporation (the “Corporation”), and (the “Indemnitee”), a director or officer of the Corporation. WHEREAS, the stockholders of the Corporation have determined, by virtue of their adoption of Article VII of the Corporation’s Certif |
|
| February 14, 2012 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2012 |
SRLS / Seracare Life Sciences Inc / BLACK HORSE CAPITAL LP - FEBRUARY 14, 2012 Passive Investment UNITED STATES SECURITIES AND EXHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SeraCare Life Sciences, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 81747T104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 14, 2012 |
Exhibit 2.1 Agreement And Plan Of Merger dated as of February 12, 2012 among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. TABLE OF CONTENTS Article 1 THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Effects of the Merger 2 Section 1.3. Closing 2 Section 1.4. Consummation of the Merger. 3 Section 1.5. Organizational Documents; Directors and Of |
|
| February 13, 2012 |
Exhibit 99.3 Dear Valued Business Partner, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven record |
|
| February 13, 2012 |
Exhibit 99.1 SeraCare Announces Definitive Agreement to be Acquired by Linden Capital Partners -Shareholders to receive $4.00 per share in cash- -Transaction valued at approximately $82 million- -SeraCare Board of Directors Unanimous in its Recommendation- -Conference Call Scheduled for 8:30 a.m. ET- MILFORD, Mass., Feb. 13, 2012 – SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life science |
|
| February 13, 2012 |
Exhibit 99.2 Dear Valued Customer, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven record of oper |
|
| February 13, 2012 |
Exhibit 99.4 Dear Valued Business Partner, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS), announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven recor |
|
| February 13, 2012 |
Exhibit 99.2 Dear Valued Customer, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven record of oper |
|
| February 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SERACARE LIFE SCIENCESCOM (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81747T104 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc |
|
| February 13, 2012 |
Exhibit 99.5 Dear SeraCare Employees, Today I am pleased to announce that we have agreed to a proposed acquisition of our company by Linden Capital Partners, a Chicago-based private equity firm that focuses on leveraged buyout investments in the healthcare and life science industries, at a price of $4.00 per share. A press announcement is being released concurrently with this email, and I have att |
|
| February 13, 2012 |
EX-99.5 6 v302364ex99-5.htm Exhibit 99.5 Dear SeraCare Employees, Today I am pleased to announce that we have agreed to a proposed acquisition of our company by Linden Capital Partners, a Chicago-based private equity firm that focuses on leveraged buyout investments in the healthcare and life science industries, at a price of $4.00 per share. A press announcement is being released concurrently wit |
|
| February 13, 2012 |
Exhibit 99.4 Dear Valued Business Partner, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS), announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven recor |
|
| February 13, 2012 |
Exhibit 99.3 Dear Valued Business Partner, It is my great pleasure to share some exciting news with you today. This morning, SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced in a press release the proposed acquisition of our company by Linden Capital Partners. A copy of the release is attached to this email for your reference. Linden is a Chicago-based private equity firm with a proven record |
|
| February 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 13, 2012 |
SeraCare Life Sciences Strategic Acquisition Conference Call Talking Points Exhibit 99.6 SeraCare Life Sciences Strategic Acquisition Conference Call Talking Points SAFE HARBOR Good morning and welcome to SeraCare Life Sciences’ conference call to discuss the signing of a definitive agreement between SeraCare and Linden LLC. Before I turn the call over to Greg Gould, Interim President and Chief Executive Officer and Chief Financial Officer, I would like to caution all par |
|
| February 13, 2012 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| February 13, 2012 |
Exhibit 99.1 SeraCare Announces Definitive Agreement to be Acquired by Linden Capital Partners -Shareholders to receive $4.00 per share in cash- -Transaction valued at approximately $82 million- -SeraCare Board of Directors Unanimous in its Recommendation- -Conference Call Scheduled for 8:30 a.m. ET- MILFORD, Mass., Feb. 13, 2012 – SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life science |
|
| February 13, 2012 |
SeraCare Life Sciences Strategic Acquisition Conference Call Talking Points Exhibit 99.6 SeraCare Life Sciences Strategic Acquisition Conference Call Talking Points SAFE HARBOR Good morning and welcome to SeraCare Life Sciences’ conference call to discuss the signing of a definitive agreement between SeraCare and Linden LLC. Before I turn the call over to Greg Gould, Interim President and Chief Executive Officer and Chief Financial Officer, I would like to caution all par |
|
| February 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-34105 SeraCare |
|
| February 10, 2012 |
SRLS / Seracare Life Sciences Inc / Coliseum Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d299275dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SeraCare Life Sciences, Inc. (Name of issuer) Common Stock, $.001 par value per share (Title of class of securities) 81747T104 (CUSIP number) December 31, 2011 (Date of event which requires filing of this statement) |
|
| February 10, 2012 |
Exhibit 99.1 SeraCare Reports 9 Percent Revenue Growth in First Quarter Fiscal Year 2012 -Product Sales Improve by 21 percent- -Cash Position Increases to $19.5 million- -Conference Call Scheduled for Today at 8:30 a.m. ET- MILFORD, Mass., Feb. 10, 2012 – SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, d |
|
| February 10, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2012 SeraCare Life Sciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34105 33-0056054 (State or other jurisdiction of incorporation) (Commiss |
|
| January 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-3 |
|
| March 19, 2009 |
Via Facsimile and U.S. Mail Mail Stop 6010 March 17, 2009 Mr. Gregory A. Gould Chief Financial Officer SeraCare Life Sciences, Inc. 37 Birch Street Milford, Massachusetts 01757 Re: SeraCare Life Sciences, Inc. Form 10-K for the Year Ended September 30, 2008 Filed on December 8, 2008 File No. 001-34105 Dear Mr. Gould: We have completed our review of your Form 10-K and have no further comments at th |
|
| February 24, 2009 |
February 24, 2009 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Ibolya Ignat Phone: (202) 551-3656 Fax: (202) 772-9217 Re: SeraCare Life Sciences, Inc. Form 10-K for the Year Ended September 30, 2008 Filed on December 8, 2008 File Number 001-34105 Ladies and Gentlemen: We are writing in response to comments contained in t |
|
| February 11, 2009 |
Via Facsimile and U.S. Mail Mail Stop 6010 February 11, 2009 Mr. Gregory A. Gould Chief Financial Officer SeraCare Life Sciences, Inc. 37 Birch Street Milford, Massachusetts 01757 Re: SeraCare Life Sciences, Inc. Form 10-K for the Year Ended September 30, 2008 Filed on December 8, 2008 File No. 001-34105 Dear Mr. Gould: We have reviewed your filing and have the following comments. We have limited |
